Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice

Atherosclerosis

Volumn 261, Issue , 2017, Pages 44-51

  Jojima, Teruo ^a   Uchida, Kohsuke ^a   Akimoto, Kazumi ^a   Tomotsune, Takanori ^a   Yanagi, Kazunori ^a   Iijima, Toshie ^a   Suzuki, Kunihiro ^a   Kasai, Kikuo ^b   Aso, Yoshimasa ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Ishibashi General Hospital   (Japan)

Author keywords

AMP Activated protein kinase; Atherosclerosis; Cell cycle arrest; Glucagon like peptide (GLP) 1; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIRAGLUTIDE; GLP1R PROTEIN, MOUSE; GLP1R PROTEIN, RAT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; IMMUNOHISTOCHEMISTRY; MALE; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; THORACIC AORTA; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE CELL; AGONISTS; ANIMAL; APOLIPOPROTEIN E KNOCKOUT MOUSE; C57BL MOUSE; CELL CULTURE; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; LIPID DIET; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN II; ANIMALS; ATHEROSCLEROSIS; CELL PROLIFERATION; CELLS, CULTURED; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINTS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETINS; LIRAGLUTIDE; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT, APOE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 85018509869     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2017.04.001     Document Type: Article

References (26)

1. [1] Ross, R., Atherosclerosis–an inflammatory disease. N. Engl. J. Med. 340 (1999), 115–126.
2. [2] Doran, A.C., Meller, N., McNamara, C.A., Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 812–819.
3. [3] Lafont, A., Guzman, L.A., Whitlow, P.L., Goormastic, M., Cornhill, J.F., Chisolm, G.M., Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ. Res. 76 (1995), 996–1002.
4. [4] Naftilan, A.J., The role of angiotensin II in vascular smooth muscle cell growth. J. Cardiovasc Pharmacol. 20 (1992), S37–S40.
5. [5] Natarajan, Rama, Scott, Stephen, Bai, Wei, Kumar, Kiran, Yerneni, V., Nadler, Jerry, Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension 33 (1999), 378–384.
6. [6] Igata, M., Motoshima, H., Tsuruzoe, K., Kojima, K., Matsumura, T., Kondo, T., Taguchi, T., Nakamaru, K., Yano, M., Kukidome, D., Matsumoto, K., Toyonaga, T., Asano, T., Nishikawa, T., Araki, E., Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ. Res. 97 (2005), 837–844.
7. [7] Nagata, D., Takeda, R., Sata, M., Satonaka, H., Suzuki, E., Nagano, T., Hirata, Y., AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 110 (2004), 444–451.
8. [8] Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007), 1409–1439.
9. [9] Drucker, D.J., The cardiovascular biology of glucagon-like Peptide-1. Cell Metab. 24 (2016), 15–30.
10. [10] Agersø, H., Jensen, L.B., Elbrønd, B., Rolan, P., Zdravkovic, M., The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45 (2002), 195–202.
11. [11] Hara, K., Aso, Y., Komatsu, T., Nakamachi, T., Sakai, Y., Takayanagi, K., Kasai, K., Inukai, T., Liraglutide increases the 24-hour heart rate by diminishing cardiac parasympathetic activity in patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-hour Holter ECG recordings. Diabetol. Int. 6 (2015), 26–32.
12. [12] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., Steinberg, W.M., Stockner, M., Zinman, B., Bergenstal, R.M., Buse, J.B., LEADER steering committee on behalf of the LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375 (2016), 311–322.
13. [13] Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., Watada, H., Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59 (2010), 1030–1037.
14. [14] Goto, H., Nomiyama, T., Mita, T., Yasunari, E., Azuma, K., Komiya, K., Arakawa, M., Jin, W.L., Kanazawa, A., Kawamori, R., Fujitani, Y., Hirose, T., Watada, H., Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem. Biophys. Res. Commun. 405 (2011), 79–84.
15. [15] Hattori, Y., Hattori, S., Wang, X., et al. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 865–870.
16. [16] Clarke, M.C., Figg, N., Maguire, J.J., Davenport, A.P., Goddard, M., Littlewood, T.D., Bennett, M.R., Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat. Med. 12 (2006), 1075–1080.
17. [17] Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., Hirano, T., Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54 (2011), 2649–2659.
18. −/- mouse model. Diab Vasc. Dis. Res. 8 (2011), 117–124.
19. [19] Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., Hirano, T., A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 54 (2014), 19–26.
20. [20] Krasner, N.M., Ido, Y., Ruderman, N.B., Cacicedo, J.M., Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One, 9, 2014, e97554.
21. [21] Ewart, M.A., Kennedy, S.A., MPK and vasculoprotection. Pharmacol. Ther. 131 (2011), 242–253.
22. [22] Stone, J.D., Narine, A., Shaver, P.R., Fox, J.C., Vuncannon, J.R., Tulis, D.A., AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury. Am. J. Physiol. Heart Circ. Physiol. 304 (2013), H369–H381.
23. [23] Nagayama, K., Kyotani, Y., Zhao, J., Ito, S., Ozawa, K., Bolstad, F.A., Yoshizumi M Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1/2 and JNK signaling pathways. PLoS One, 10, 2015, e0137960.
24. [24] Begum, N., Hockman, S., Manganiello, V.C., Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. J. Biol. Chem. 286 (2011), 26238–26249.
25. [25] Hayashi, S., Morishita, R., Matsushita, H., Nakagami, H., Taniyama, Y., Nakamura, T., Aoki, M., Yamamoto, K., Higaki, J., Ogihara, T., Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 35:1 Pt 2 (2000), 237–243.
26. [26] Koska, J., Sands, M., Burciu, C., D'Souza, K.M., Raravikar, K., Liu, J., Truran, S., Franco, D.A., Schwartz, E.A., Schwenke, D.C., D'Alessio, D., Migrino, R.Q., Reaven, P.D., Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 64 (2015), 2624–2635.